While testing genes to treat glaucoma by reducing pressure inside the eye, University of Wisconsin-Madison scientists stumbled onto a problem: They had trouble getting efficient gene delivery to the cells that act like drains to control fluid pressure in the eye.
Genes can't work until they enter a cell.
In an effort to improve gene transfer to treat the blinding disease glaucoma, the front of an untreated eye (left) is compared to an eye (right) pretreated with a gene delivery enhancer. The green marker reveals the expression of a new gene in the trabecular meshwork, which drains fluid from the eye and is usually blocked in glaucoma. The green band resulting from gene transfer is denser and wider in the enhancer-treated eye.
Credit: Curtis Brandt/Paul Kaufman, University of Wisconsin-Madison
Glaucoma, one of the most common blinding diseases, is caused by excess pressure inside the eye, usually due to a clog in the fluid drain. "Most glaucoma can be treated with daily drug treatment," says Paul Kaufman, professor of ophthalmology and visual sciences at the University of Wisconsin-Madison.
"Replacement genes could, theoretically, restore normal fluid flow for years on end, without requiring daily self-administration of eye drops that is inconvenient and may have local or even systemic side effects."
In a study published today in the scientific journal Investigative Ophthalmology and Visual Science, Kaufman and Curtis Brandt, a fellow professor of ophthalmology and visual sciences at UW-Madison, showed an improved tactic for delivering new genes into the drain, called the trabecular meshwork.
The colleagues have been testing a vector based on feline immunodeficiency virus (FIV) to deliver the genes. Like the related human immunodeficiency virus, FIV can insert genes into the host's DNA. The eye's innate defenses against FIV, however, interfered with the delivery.
Virus particles contain genes wrapped in a protein coat and then a lipid membrane. After the virus enters the cell and sheds its membrane, defensive molecules from the host can "drag the virus particle to the cell's garbage disposal, called the proteasome, where it is degraded," Brandt says. "We wanted to know if temporarily blocking the proteasome could prevent the destruction of the gene delivery vector and enhance delivery."
In the current study, FIV virus carrying a marker protein was placed on cells of the trabecular meshwork, with or without a chemical that blocks proteasomes.
Above a dosage threshold, the treatment roughly doubled the transfer of genes entering the target cells, Brandt says. The new genes also spread more uniformly across the meshwork tissue. Delivering more copies of the gene should give a greater therapeutic effect, opening the meshwork drain and reducing pressure inside the eye.
The present study concerns the tools for transferring genes, not the genes themselves, Brandt says. But even before the current study, he says he and Kaufman "have already identified at least two genes that could unplug the drain."
In the long struggle to replace genes and cure disease, "eyes have been one of the big success stories," Brandt says. A blinding eye disease called Leber's congenital amaurosis damages the function of cells that keep the light-sensitive cells healthy; replacing the mutated genes has preserved and even improved vision in young patients. Approval for this gene therapy is now pending at the Food and Drug Administration.
To forestall danger from injecting a virus, "We take out pretty much all of the virus' genes, so it has no chance to replicate and spread from where it's initially injected," says Brandt.
Although the technique does interfere with the anti-viral defense in the eye, the effect is temporary. "You encounter the drug once, then it is metabolized, and the innate inhibition is lost," Brandt says.
"We have shown that this strategy does work in eye organ culture," Brandt says. "Once we do further work on efficiency and identify which gene to deliver, then we are probably ready to move toward clinical trials."
The research was supported by Bright Focus Foundation, Research to Prevent Blindness, the National Institutes of Health, and other sources.
David Tenenbaum, 608-265-8549, email@example.com
Curtis Brandt | EurekAlert!
Hot cars can hit deadly temperatures in as little as one hour
24.05.2018 | Arizona State University
3D images of cancer cells in the body: Medical physicists from Halle present new method
16.05.2018 | Martin-Luther-Universität Halle-Wittenberg
The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.
Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...
A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.
The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...
At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.
At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...
There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?
At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...
So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics
Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...
25.05.2018 | Event News
02.05.2018 | Event News
13.04.2018 | Event News
25.05.2018 | Event News
25.05.2018 | Machine Engineering
25.05.2018 | Life Sciences